Adam Hendricson, Ph.D.
Dr. Hendricson is a specialist in early pre-clinical drug hunting, with a focus on the hit-to-lead process and translational in vitro models. Prior to joining YCMD in 2016, he spent the bulk of his career in biotech and pharma, most recently in the applied biotechnology group at Bristol-Myers Squibb. He has contributed to discovery programs in the areas of psychiatry, analgesia, neurodegeneration, heart failure, and oncology, including molecules that entered Phase I clinical trials. Dr. Hendricson earned a Ph.D. in Pharmacology from Tulane University in 2002, followed by a post-doctoral fellowship at the University of Texas at Austin.